PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, 06520, USA.\', \'Section of Pulmonary and Critical Care and Sleep Medicine, Department of Internal Medicine, Yale University School of Medicine, S440, 300 Cedar Street, New Haven, CT, 06520, USA.\', \'Section of Pediatric Pulmonary, Allergy, Immunology and Sleep Medicine, Department of Pediatrics, Yale School of Medicine, New Haven, CT, 06520, USA.\', \'Department of Internal Medicine, Yale School of Medicine, New Haven, CT, 06520, USA.\', \'Section of Pulmonary and Critical Care and Sleep Medicine, Department of Internal Medicine, Yale University School of Medicine, S440, 300 Cedar Street, New Haven, CT, 06520, USA. charles.delacruz@yale.edu.\', \'Department of Microbial Pathogenesis, Yale School of Medicine, New Haven, CT, 06520, USA. charles.delacruz@yale.edu.\', \'Section of Pulmonary and Critical Care and Sleep Medicine, Department of Internal Medicine, Yale University School of Medicine, S440, 300 Cedar Street, New Haven, CT, 06520, USA. lokeshkumar.sharma@yale.edu.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1186/s12879-020-05730-z
?:doi
?:hasPublicationType
?:journal
  • BMC infectious diseases
is ?:pmid of
?:pmid
?:pmid
  • 33430799
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.576
?:rankingScore_hIndex
  • 80
is ?:relation_isRelatedTo_publication of
?:title
  • JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all